- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03584412
OPEN Feasibility Study
Feasibility Randomized-Controlled Trial of Online Acceptance and Commitment Therapy for Painful Peripheral Neuropathy in People Living With HIV: The OPEN Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The human immunodeficiency virus (HIV) is a major health problem in the United Kingdom and worldwide. Neuropathic pain in the feet related to peripheral neuropathy is one of the most common symptoms associated with HIV. This pain is difficult to treat and medications are not effective. Chronic pain in people with HIV is related to higher levels of disability and poor quality of life.
Psychological treatments like cognitive behaviour therapy (CBT) can improve quality of life for people with chronic pain in general (not HIV-related), and there have been efforts to provide more accessible versions of CBT over the Internet. However, it is not known whether Internet-based CBT is helpful for people with HIV and chronic pain.
The current trial will explore the feasibility of a newly developed form of online CBT called Acceptance and Commitment Therapy (which we have called "ACT OPEN") for people with HIV and painful peripheral neuropathy. Participants will be recruited from HIV clinics in London, UK. Participants will be randomly chosen to receive the new ACT OPEN treatment right away or after waiting for 5 months. The treatment lasts for 8 weeks. Participants will complete self-report questionnaires to assess pain, functioning, and mood at the beginning of the study and 8 weeks and five months later.
The purpose of this study is to examine the feasibility of a larger trial evaluating the impact of online ACT for people with HIV and chronic pain in their feet. Key feasibility parameters that will be evaluated will include an estimate of the recruitment and retention rates, treatment completion rate and satisfaction, and an estimate of the effect size of changes in standard pain outcome measures.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE1 9RT
- Guy's and St Thomas' Hospital NHS Foundation Trust
-
London, United Kingdom, SE1 9RT
- Chelsea And Westminster Hospital
-
London, United Kingdom, SE1 9RT
- King's College Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 years or older living with HIV.
- Positive screen for peripheral sensory neuropathy, as indicated by the presence of self-reported bilateral foot pain in a symmetrical distribution (Woldeamanuel et al., 2016).
- Positive screen for symptoms of neuropathic pain in the feet, as indicated by a score of 3 or more on the patient reported outcomes section of the DN4 Neuropathic Pain Interview (Bouhassira et al., 2005; Bouhassira, Lantéri-Minet, Attal, Laurent, & Touboul, 2008)
- Pain in the feet present most days for at least 3 months.
- Average pain intensity over the past week of at least 4 on a scale from 0 (no pain) to 10 (pain as bad as you can imagine) (Zelman, Dukes, Brandenburg, Bostrom, & Gore, 2005).
- Average interference of pain with daily activities over the past 3 months is at least 4 on a scale ranging from 0 (no interference) to 10 (unable to carry on any activities) (Von Korff, Ormel, Keefe, & Dworkin, 1992).
- At least moderate symptoms of depression in the past 2 weeks, as indicated by a score of at least 10 on the PHQ-9 (Kroenke et al., 2001).
Exclusion Criteria:
- Severe symptoms of depression, as indicated by a PHQ-9 score of 23 or greater.
- Active suicidal ideation, as reflected by a score of 2 or greater on the PHQ-9 item 9 and current intent or plan to self-harm.
- A positive screen of self-reported alcohol or other substance abuse in the past 3 months as reflected by an ASSIST-Lite score of at least 3 for alcohol or at least 2 for other substances, including misuse of prescribed opioids.
- Presence of any other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, post-traumatic stress disorder) that is currently unstable or poorly controlled and likely to interfere with treatment engagement, as judged by a clinical psychologist conducting the screening.
- Currently receiving another form of regular psychotherapy (i.e., weekly appointments); involvement in psychotherapy or counselling appointments occurring less than weekly will be permitted.
- Changes to medications for mood and pain for the last 6 weeks.
- Major surgical procedure for any reason planned within the next 5 months.
- Unable to complete study procedures in English
- Unwilling to commit approximately 1-2 hours per week to complete the treatment and to do so over the Internet (note: access to a tablet/wifi will be provided for otherwise eligible participants who do not have such access; therefore, lack of internet access will not be an exclusion criterion)
- Unable to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ACT OPEN
Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
|
Participants will access the ACT OPEN treatment through a secure online platform.
Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting).
Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference.
Therapists will provide individualised feedback.
ACT OPEN consists of 12 sessions over 6 weeks.
Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
|
OTHER: Waiting List Control
Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
|
Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described.
A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV.
Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control.
However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment.
In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment Rate
Time Frame: Baseline
|
Proportion of participants randomised relative to total trial referrals
|
Baseline
|
Retention Rate
Time Frame: 8 weeks post-randomisation
|
Proportion of participants who complete follow-up questionnaires
|
8 weeks post-randomisation
|
Treatment Completion Rate
Time Frame: 8 weeks following receipt of treatment
|
We expect 70% of participants to complete at least 8/12 ACT OPEN sessions
|
8 weeks following receipt of treatment
|
Treatment Satisfaction
Time Frame: 8 weeks following receipt of treatment
|
Total score on the Client Satisfaction Questionnaire (range: 8-32; higher scores reflect greater satisfaction)
|
8 weeks following receipt of treatment
|
Data Completeness
Time Frame: Baseline
|
Proportion of missing items on individual questionnaires
|
Baseline
|
Other Treatments Accessed
Time Frame: 8 weeks post-randomisation
|
Self-reported frequency of use of other treatments (e.g., medical, complimentary, etc)
|
8 weeks post-randomisation
|
Patient's impression of overall change during treatment
Time Frame: 8 weeks following receipt of treatment
|
Score on single item Patient Global Impression of Change Rating (range: 1 (very much improved) to 7 (very much worse))
|
8 weeks following receipt of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Interference
Time Frame: 8 weeks post-randomisation
|
Brief Pain Inventory average of pain interference subscale items score (range 0-10; higher scores reflect greater pain interference)
|
8 weeks post-randomisation
|
Social and Occupational Functioning
Time Frame: 8 weeks post-randomisation
|
Work and Social Adjustment Scale Total Score (range: 0-40; higher scores reflect greater impairment in social and occupational functioning)
|
8 weeks post-randomisation
|
Depression Symptoms
Time Frame: 8 weeks post-randomisation
|
PHQ-9 Total Score (range: 0-27; higher scores reflect more severe depression symptoms)
|
8 weeks post-randomisation
|
Pain Acceptance
Time Frame: 8 weeks post-randomisation
|
Chronic Pain Acceptance Questionnaire--8 Item Version Total Score (range: 0-48; higher scores reflect greater acceptance)
|
8 weeks post-randomisation
|
Pain Intensity
Time Frame: 8 weeks post-randomisation
|
Average of the Brief Pain Inventory pain intensity items (range: 0-10; higher scores reflect more intense pain)
|
8 weeks post-randomisation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Whitney Scott, PhD, Whitney Scott
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 236730
- PDF-2015-08-059 (OTHER_GRANT: National Institute for Health Research)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Neuropathy
-
Targeted Medical PharmaUnknownDiabetic Neuropathy | Chemotherapy Induced Neuropathy | HIV Neuropathy | Trauma Induced NeuropathyUnited States
-
NYU Langone HealthColumbia UniversityCompletedHIV Infections | HIV | Peripheral Neuropathy | AIDSUnited States
-
Imperial College LondonCompletedHIV | Neuropathic Pain | Sensory NeuropathyUnited Kingdom
-
University of Houston DowntownNot yet recruiting
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)WithdrawnPolyneuropathy | HIV-associated NeuropathyUnited States
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS); PPD; Ortho Biotech...WithdrawnHIV Infections | Neuropathy
-
National Center for Complementary and Integrative...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHIV Infections | Peripheral NeuropathyUnited States, Puerto Rico
-
King's College LondonImperial College London; University College, London; Chelsea and Westminster...Completed
-
National Center for Complementary and Integrative...CompletedHIV Infections | Peripheral NeuropathiesUnited States
Clinical Trials on ACT OPEN
-
Peking UniversityBeijing Municipal Science & Technology CommissionUnknown
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy SubjectsNetherlands
-
Idorsia Pharmaceuticals Ltd.Completed
-
Azusa Pacific UniversityWithdrawnAnxiety Disorders | Stress Disorders, Traumatic | AnxietyUnited States
-
Karolinska InstitutetRegion Stockholm; Forte; Stiftelsen Frimurarna BarnhusetActive, not recruitingDepression | Stress, Psychological | Intellectual Disability | Anxiety | Neurodevelopmental Disorders | Traumatic Brain Injury | Autism Spectrum Disorder | Parents | Attention Deficit Hyperactivity Disorder | Physical DisabilitySweden
-
University of CoimbraFundação para a Ciência e a TecnologiaUnknown
-
University College DublinCompletedInflammatory Bowel DiseaseIreland
-
Idorsia Pharmaceuticals Ltd.Terminated
-
Georgia State UniversityRecruiting